论文部分内容阅读
为探讨检测血清糖抗原 19- 9(CA19- 9)与糖抗原 2 42 (CA2 42 )对原发性和继发性肝癌的诊断意义 ,以免疫酶法检测肝癌患者血清 CA 19- 9与 CA2 42 ,分别与良性肝病与正常健康组比较分析。结果显示原发性和继发性肝癌与良性肝病和健康对照组比较均有非常显著性差别 (P<0 .0 1)。 CA 19- 9和 CA2 42对原发性肝癌诊断敏感性分别为 5 6 .6 %和 2 2 .6 % ,对继发性肝癌诊断敏感性分别为 6 0 .7%和 5 7.4%。故认为 ,检测血清 CA19- 9对原发性肝癌和 CA 19- 9与 CA 2 42对继发性肝癌的诊断都有较高临床应用价值
In order to explore the significance of detecting serum CA19-9 (CA19-9) and carbohydrate antigen242 (CA242) in the diagnosis of primary and secondary liver cancer, the levels of serum CA 19-9 and CA2 42, respectively, compared with benign liver disease and normal health group. The results showed that there was a significant difference between primary and secondary liver cancer and benign liver disease and healthy controls (P <0.01). The sensitivity of CA 19-9 and CA2 42 to the diagnosis of primary liver cancer were 56.6% and 22.6%, respectively. The sensitivity of CA 19-9 and CA2 42 to the diagnosis of HCC were 60.7% and 57.4%, respectively. Therefore, the detection of serum CA19-9 on the diagnosis of primary liver cancer and CA 19-9 and CA 2 42 in patients with secondary liver cancer have a higher clinical value